CEL-SCI’s Multikine® Granted Saudi FDA NADR Designation, Advancing Commercialization Plans

CEL-SCI’s Multikine Receives Saudi Arabia’s NADR Designation, Advancing Potential First Global Commercial Launch in 2027

CEL-SCI Corporation, a clinical-stage biotechnology company developing investigational immunotherapy treatments for cancer, announced that its Multikine cancer immunotherapy has secured official designation through the SFDA’s NADR program in Saudi Arabia.

The designation application was successfully submitted by Amarox, CEL-SCI’s in-country regulatory and commercialization partner in Saudi Arabia. The achievement represents an important step in the company’s regulatory and commercial development strategy as it works toward introducing Multikine to patients with locally advanced head and neck cancer.

The NADR designation provides Multikine with access to an accelerated regulatory review framework intended to facilitate the development and availability of innovative medicines addressing serious diseases and significant unmet medical needs.

Following the designation, CEL-SCI and Amarox are preparing to advance the next stage of the regulatory process by submitting an MAA to the SFDA within approximately two to three months. Under the recently enacted SFDA guidance, products receiving NADR designation are eligible for priority assessment with a target review timeframe of 160 working days.

This accelerated assessment framework could support a potential commercial introduction of Multikine in Saudi Arabia during 2027 or early 2028. However, the anticipated timeline remains dependent on the submission, review, and approval of the marketing authorization application by the Saudi regulatory authority.

The development also positions Saudi Arabia as a potential first global commercial market for Multikine, representing an important component of CEL-SCI’s international commercialization strategy.

Initially, Multikine will be supplied from CEL-SCI’s manufacturing facility in the United States, allowing the company to establish its commercial presence in Saudi Arabia while leveraging its existing manufacturing infrastructure.

Saudi Arabia’s NADR Designation Advances Multikine’s Regulatory Pathway

The NADR program was launched by the Saudi Food and Drug Authority in August 2026 as part of the Kingdom’s broader efforts to transform its healthcare sector under Saudi Vision 2030 and the National Biotechnology Strategy.

The initiative is designed to accelerate the regulatory evaluation of innovative therapies targeting serious diseases with substantial unmet medical needs. Through this framework, the SFDA aims to facilitate patient access to advanced medicines while strengthening the country’s position as an emerging center for biotechnology, pharmaceutical innovation, and healthcare development.

For CEL-SCI, receiving NADR designation represents an important regulatory opportunity to advance Multikine toward potential commercialization in a market that is actively investing in innovative healthcare solutions.

The designation provides several potential advantages for the company’s development and commercialization plans.

One of the most significant benefits is eligibility for priority regulatory assessment under the SFDA’s submission guidance, effective January 1, 2027. The framework establishes a target assessment period of 160 working days for eligible products.

This accelerated review timeline could help reduce the time required for regulatory evaluation compared with standard assessment pathways, although the actual approval timeline will depend on the completeness of the application and the SFDA’s evaluation.

The NADR framework also provides opportunities for dedicated scientific advice and regulatory collaboration. These mechanisms are intended to support companies developing innovative therapies by offering tailored evaluation approaches and facilitating communication with regulatory authorities.

Additionally, the program includes streamlined access pathways designed to support the introduction of potentially high-impact medicines to patients with serious diseases.

For Multikine, these regulatory advantages could help CEL-SCI advance its commercialization strategy while addressing the treatment needs of patients with locally advanced oral cavity squamous cell carcinoma.

CEL-SCI Highlights Strategic Importance of Saudi Arabia

Commenting on the regulatory milestone, Geert Kersten, Chief Executive Officer of CEL-SCI Corporation, emphasized the importance of the SFDA’s accelerated regulatory framework and its alignment with Saudi Arabia’s healthcare transformation objectives.

“The Saudi FDA has demonstrated extraordinary global regulatory leadership by establishing the NADR program,” Kersten said.

He noted that the framework aligns with Saudi Vision 2030’s objective of bringing advanced healthcare innovations and medical technologies into the Kingdom.

According to Kersten, CEL-SCI is prioritizing Saudi Arabia as the potential first global commercial market for Multikine because of the regulatory opportunities provided by the NADR program and the country’s commitment to expanding access to innovative therapies.

The CEO also highlighted the importance of the company’s partnership with Amarox in supporting the regulatory and commercial transition.

Amarox brings local regulatory knowledge and commercialization capabilities that are expected to support the preparation of the marketing authorization application and the subsequent introduction of Multikine into the Saudi market, subject to approval.

Kersten further emphasized that the collaboration extends beyond the commercialization of a single investigational medicine. It also supports Saudi Arabia’s broader objective of developing localized biopharmaceutical infrastructure, including marketing, distribution, logistics, and commercial capabilities.

He stated that the partnership is intended to reduce the financial and operational risks associated with CEL-SCI’s commercial transition while advancing the company’s goal of bringing potentially life-extending treatment options to patients with head and neck cancer.

CEL-SCI also confirmed that initial commercial supplies of Multikine will come from its U.S.-based manufacturing facility.

Amarox Partnership Supports Local Commercialization and Biotechnology Development

Saudi Amarox’s role is central to CEL-SCI’s plans for entering the Saudi pharmaceutical market.

Under the strategic partnership announced in May 2026, Amarox serves as CEL-SCI’s local regulatory representative and exclusive commercial distributor for Multikine in Saudi Arabia.

The collaboration is designed to combine CEL-SCI’s immunotherapy development and manufacturing capabilities with Amarox’s regional regulatory expertise and commercial infrastructure.

Dr. Abdullah Alzomaie, Founder and Chief Executive Officer of Saudi Amarox, described the collaboration as an important development in the company’s strategy to expand into innovative medicines, advanced therapies, and biotechnology.

“Our partnership with CEL-SCI represents an important step in Saudi Amarox’s strategy to expand into innovative medicines, advanced therapies, and biotechnology,” Alzomaie said.

He also expressed appreciation for CEL-SCI’s confidence in Amarox as its regional partner and highlighted the NADR designation as an important early achievement in their collaboration.

According to Alzomaie, the regulatory milestone reflects the supportive environment Saudi Arabia is developing through Vision 2030 to encourage medical innovation, scientific research, and the introduction of advanced therapies.

He described the partnership as the beginning of a long-term collaboration focused on bringing innovative medicines into the region and contributing to the development of the Kingdom’s biotechnology sector.

The partnership also establishes a capital-efficient commercialization structure for CEL-SCI.

Under the agreement, the companies will operate through a 50%/50% net revenue-sharing model. Amarox will utilize its fully funded in-country marketing, logistics, and sales infrastructure to support the commercialization of Multikine.

This arrangement is intended to allow CEL-SCI to access the Saudi market without independently establishing an extensive commercial organization in the country.

The agreement also includes an option to expand the localized commercial framework into other Gulf Cooperation Council (GCC) markets.

These potential expansion markets include:

  • United Arab Emirates
  • Kuwait
  • Qatar
  • Bahrain
  • Oman

If exercised and successfully implemented, the expansion option could provide CEL-SCI with an opportunity to extend its regional commercialization strategy beyond Saudi Arabia and establish a broader presence across the Gulf region.

Multikine’s Clinical Development Supported by Phase 3 Survival Findings

A central component of CEL-SCI’s regulatory strategy is the clinical evidence generated from its Phase 3 development program evaluating Multikine in patients with locally advanced head and neck cancer.

The company intends to seek marketing authorization in Saudi Arabia for the same target patient population defined in its planned U.S. registration study.

This population includes newly diagnosed, previously untreated adult patients with locally advanced, resectable oral cavity squamous cell carcinoma (OCSCC), with no lymph node involvement and low or zero tumor PD-L1 expression.

Oral cavity squamous cell carcinoma is a type of head and neck cancer that develops in the tissues lining the mouth. Treatment typically involves a combination of surgery, radiation therapy, and chemotherapy, depending on disease characteristics and individual patient circumstances.

Despite established treatment approaches, patients with locally advanced disease may continue to face significant risks of recurrence and mortality. This highlights the need for additional therapeutic strategies that could improve long-term survival outcomes.

CEL-SCI’s Multikine is being developed as a neoadjuvant immunotherapy, meaning it is administered before conventional cancer treatments such as surgery, radiation, and chemotherapy.

The company’s approach is designed to activate the patient’s existing immune system early in the treatment process, following diagnosis and before standard-of-care interventions.

In its Phase 3 clinical program, Multikine was evaluated as a treatment administered before standard-of-care therapy in patients with locally advanced head and neck cancer.

According to CEL-SCI, the Phase 3 study represented the largest clinical investigation conducted in locally advanced head and neck cancer at the time of the reported findings.

The company highlighted significant survival differences in the specific patient subgroup that it intends to target through its planned registration strategy.

The reported five-year overall survival rate was 73% among patients receiving Multikine before standard-of-care treatment, compared with 45% among patients receiving standard-of-care treatment alone.

The company also reported a 66% relative reduction in the risk of death compared with standard-of-care treatment alone, with a hazard ratio of 0.34.

The reported difference was statistically significant, with a p-value of 0.0015.

These findings form an important part of CEL-SCI’s clinical and regulatory rationale for pursuing marketing authorization in the defined patient population.

However, the reported results apply to the specific subgroup described by the company and should not be interpreted as evidence of equivalent benefits across all patients with head and neck cancer.

Multikine’s Neoadjuvant Approach Focuses on Early Immune Activation

Multikine is designed to be administered locally over approximately three weeks immediately following cancer diagnosis and before patients undergo surgery, radiation therapy, or chemotherapy.

The treatment strategy is based on the concept of activating the patient’s immune system while it remains intact, before the potential effects of conventional cancer treatments.

The immune system plays an important role in identifying and responding to cancer cells. However, tumors can develop mechanisms that allow them to avoid immune recognition or suppress immune responses.

By administering Multikine before standard-of-care treatment, CEL-SCI aims to stimulate immune activity during an early stage of the treatment process.

The company’s development strategy focuses on evaluating whether this neoadjuvant immune activation approach can improve long-term outcomes in appropriately selected patients.

The clinical results highlighted by CEL-SCI, particularly the reported five-year overall survival findings, provide the foundation for its planned regulatory submissions.

The company intends to pursue a focused indication rather than seeking broad authorization across all head and neck cancer populations.

This approach is reflected in the planned U.S. registration study population and the proposed Saudi marketing authorization strategy.

Commercialization Strategy Focuses on Capital Efficiency and Regional Expansion

The NADR designation is expected to support CEL-SCI’s transition from clinical development toward potential commercial operations.

Through its agreement with Amarox, the company has established a commercialization framework that combines local market expertise with an established infrastructure for marketing, distribution, and logistics.

The 50%/50% net revenue-sharing arrangement is intended to provide a capital-efficient approach to entering Saudi Arabia.

Rather than independently building a complete commercial organization, CEL-SCI can rely on Amarox’s in-country capabilities to support the regulatory and commercial activities associated with Multikine.

The initial supply of the investigational therapy will be sourced from CEL-SCI’s U.S.-based manufacturing facility.

This arrangement provides a planned supply structure for the initial Saudi commercialization phase, subject to regulatory authorization and applicable requirements.

The option to extend the agreement into additional GCC countries could further expand the commercial opportunity.

The Gulf region represents an important potential market for innovative pharmaceutical products as healthcare systems continue to invest in advanced treatments, biotechnology capabilities, and improved patient access.

CEL-SCI’s collaboration with Amarox is intended to establish a foundation for potential regional growth while supporting Saudi Arabia’s localization and healthcare development objectives.

First Berlin Continues to Support the Partnership

First Berlin, an investment banking and financial advisory firm based in Berlin, Germany, which facilitated the strategic partnership between CEL-SCI and Amarox, continues to support the companies as the Multikine program advances toward regulatory submission and potential commercialization in Saudi Arabia.

Its continued involvement comes as the partners prepare for the next stages of regulatory engagement and commercial planning.

The NADR designation provides an important regulatory milestone, while the planned MAA submission represents the next major step toward potential market authorization.

Next Steps Toward Potential 2027–2028 Market Introduction

With the NADR designation secured, CEL-SCI and Amarox are preparing to submit the Multikine marketing authorization application to the SFDA within the next two to three months.

The application will be evaluated under the regulatory framework applicable to the NADR program, which provides eligible products with a target assessment timeframe of 160 working days.

If the application progresses according to the anticipated schedule and receives regulatory approval, CEL-SCI could potentially begin commercial sales of Multikine in Saudi Arabia in 2027 or early 2028.

The company will initially rely on its U.S.-based manufacturing facility to supply the Saudi market, while Amarox will manage its local regulatory representation and exclusive commercial distribution responsibilities.

The latest regulatory development strengthens CEL-SCI’s international commercialization plans and provides a potential pathway for introducing Multikine in a market actively investing in biotechnology and advanced healthcare solutions.

Although marketing authorization remains subject to SFDA review and approval, the NADR designation marks a significant step toward CEL-SCI’s goal of bringing its investigational immunotherapy to patients with locally advanced oral cavity cancer.

Through its collaboration with Amarox, the company is working to establish a commercial framework that could eventually extend beyond Saudi Arabia into additional GCC markets, while supporting the Kingdom’s broader ambitions under Saudi Vision 2030.

About Multikine

Multikine is a novel cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated locally advanced head and neck cancer. It is manufactured at scale, stored in a vial, and injected directly around the tumor. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest locally advanced head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system “target” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been administered to over 740 patients and has an excellent safety profile compared to other cancer drugs. It has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter